Literature DB >> 31100208

Medication taking behaviors in patients taking warfarin versus direct oral anticoagulants: A systematic review.

Anjana Mohan1, Matthew A Wanat2, Susan M Abughosh1.   

Abstract

Introduction: This article aims to compare medication adherence and persistence between warfarin and direct oral anticoagulants (DOACs) and identify reported adherence barriers. As with other chronic illness, medication nonadherence continues to be a problem and appropriate adherence to long-term anticoagulation therapy is needed to improve patient health outcomes and to reduce health expenditure associated with hospitalizations and emergency visits. Areas covered: Warfarin and DOACs such as apixaban, rivaroxaban, edoxaban, and dabigatran have demonstrated effectiveness in the management of atrial fibrillation (AF), deep vein thrombosis (DVT), and pulmonary embolism (PE). Adherence and long-term persistence to oral anticoagulants is highly associated with reduced adverse events. A systematic literature search from 2013 to 2018 examined the primary outcome of adherence and persistence. Expert opinion: Currently, warfarin is less preferred over DOACs due to associated complications like narrow therapeutic window, inconvenience, and increased risk of adverse events. At the same time, the lack of monitoring with DOACs in combination with cost issues may negatively impact medication adherence. Examining adherence barriers identified in the literature is the first step to designing effective interventions aimed at enhancing adherence in this high-risk population.

Entities:  

Keywords:  Warfarin; barriers; direct oral anticoagulants; medication adherence; persistence

Mesh:

Substances:

Year:  2019        PMID: 31100208     DOI: 10.1080/14779072.2019.1620600

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  4 in total

1.  Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center.

Authors:  Sweta Meet Patel; Tina Wang; Desire Lashalle Outler; Jennifer Elliott; Michael Knauss; Samuel K Peasah; Mikhail Akbashev
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

Review 2.  Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation.

Authors:  Miney Paquette; Lawrence Mbuagbaw; Alfonso Iorio; Robby Nieuwlaat
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2021-05-23

3.  Cost Conversations About Anticoagulation Between Patients With Atrial Fibrillation and Their Clinicians: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Celia C Kamath; Rachel Giblon; Marlene Kunneman; Alexander I Lee; Megan E Branda; Ian G Hargraves; Angela L Sivly; Fernanda Bellolio; Elizabeth A Jackson; Bruce Burnett; Haeshik Gorr; Victor D Torres Roldan; Gabriella Spencer-Bonilla; Nilay D Shah; Peter A Noseworthy; Victor M Montori; Juan P Brito
Journal:  JAMA Netw Open       Date:  2021-07-01

4.  Reasons for discontinuing oral anticoagulation therapy for atrial fibrillation: a systematic review.

Authors:  Jackie Buck; Julia Fromings Hill; Alison Martin; Cassandra Springate; Bikramaditya Ghosh; Rachel Ashton; Gerry Lee; Andrzei Orlowski
Journal:  Age Ageing       Date:  2021-06-28       Impact factor: 10.668

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.